Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
130 participants
OBSERVATIONAL
2020-09-24
2023-09-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Clinical Benefits in Optimized Remote HF Patient Management
NCT01482598
Preliminary Research Evaluation for Ambulatory Leadless Electrocardiogram Recorder Trial
NCT05357716
PROSPECT: Predictors of Response to Cardiac Re-Synchronization Therapy
NCT00253357
Resynchronization/Defibrillation for Ambulatory Heart Failure Trial
NCT00251251
Monitoring of Arrhythmias and HRV in Patients With Heart Failure Treated With the CRT Pacemaker Renewal TR2
NCT00180531
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Coala Heart Monitor
ECG monitoring
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Newly diagnosed moderate to severe heart failure (NYHA II-IV and left ventricular ejection fraction ≤ 40%)
Exclusion Criteria
* Pacemaker
* Cardiac resynchronization device
* Indications for OAC treatment (also low molecular weight heparin) due to atrial arrhythmias, mechanical heart valve, deep vein thrombosis, or pulmonary embolism.
* Expected survival ≤ 6 months
* Absolute contraindications for starting OAC treatment
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Coala Life, Inc
INDUSTRY
Herlev and Gentofte Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Morten Lamberts
Associate Professor and Research Director
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Department of Cardiology, Herlev & Gentofte Hospital
Copenhagen, Hellerup, Denmark
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Morten Kjøbæk Lamberts, MD, PhD
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
P-2020-551
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.